FPT-SOFTWARE
31.7.2024 04:01:26 CEST | Business Wire | Press release
Global leading IT company FPT Software announced that its Chief Artificial Intelligence Officer, Dr. Nguyen Xuan Phong, has been listed on the 2024-2025 Artificial Intelligence 150 (AI150) list by Constellation Research, recognizing leaders pioneering AI transformation efforts around the globe. The Chief AI Officer is the only executive from a Southeast Asian enterprise to be named to this elite list.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730156983/en/
(Graphic: Business Wire)
2024-2025 Artificial Intelligence 150 (AI150) is an inaugural initiative by Constellation Research, a technology research and advisory firm based in Silicon Valley and one of the world’s leaders in digital transformation and disruptive technology consulting. The AI150 celebrates top global executives leading AI transformation efforts globally, across multiple industries, and in various roles including Chief AI Officer, Chief Digital Officer, Chief Technology Officer, and Chief Executive Officer.
The selection process lasts six months, from nomination by industry leaders to extensive reference checks for real projects, leadership, mentorship abilities, and standing among colleagues and peer groups. Each leader on the AI150 demonstrates a comprehensive understanding of how the world is responding to artificial intelligence and how new technologies can be leveraged for future innovation.
The accolade is a testament to Dr. Nguyen Xuan Phong and FPT Software’s commitment to being a pioneer, practitioner, and advocate for the acceleration of Intelligence Transformation while using AI to address key business and technology challenges of global enterprises. Others featured in the 2024-2025 list include executives from global technology leaders like SAP, Adobe, Google, Intel, Facebook, and Microsoft, as well as Fortune 500 enterprises such as Ford Motor, United Airlines, TotalEnergies, Merck, and Schneider Electric.
FPT Software and its parent company, FPT Corporation, have over a decade of experience in the research and development of AI solutions since the establishment of its first AI Research Lab in 2019, serving as a comprehensive research, development, and learning facility for 20,000 tech personnel. In his role, Dr. Nguyen Xuan Phong heads a robust global AI Center that drives AI research and industrial application for FPT Software’s global clients, strategizing AI integration, fostering innovation, boosting productivity, and ensuring ethical AI practices. He played an instrumental role in FPT Corporation’s global partnerships with leading AI players such as NVIDIA, Mila, Landing AI, AITOMATIC, and the recent founding membership of the AI Alliance led by IBM and Meta.
“At FPT Software, we believe AI is not just about algorithms; it’s about transforming organizations, industries, and people’s lives. We are committed to expanding our AI ecosystems and embedding AI and Generative AI into all of our solutions and services, as this technology will fundamentally transform everything in business and our society,” said Dr. Nguyen Xuan Phong. “It is my pleasure to be recognized in this esteemed list, and I look forward to engaging with Constellation Research and the AI150 community to participate in global conversations and research studies on AI and business transformation.”
“In the Age of AI, we can expect AI to be infused in every part of the business. This rapidly evolving field has pioneers, policy shapers, and practitioners that will transform industries,” noted R “Ray” Wang, founder and CEO at Constellation Research. “The AI150 is our attempt of identifying a small slice of the innovators and change agents that are making substantial contributions to the advancement of this revolution.”
In addition to his work with FPT Software, Dr. Nguyen Xuan Phong is a decorated scholar with a PhD/EngD from the University of Tokyo, majoring in AI. He also made significant contributions to AI research at Hitachi in Japan and the Mila, Quebec AI Institute in Canada.
The full listing can be found here: Artificial Intelligence 150 2024 - 2025 | Constellation Research Inc.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730156983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 10:00:00 CEST | Press release
- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study - Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability t
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 10:00:00 CEST | Press release
Combined market up 46%, led by 64% growth in cloud servicesManaged services up 21%, as companies seek cost savings to fund AI Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasin
Maureen Mahr von Staszewski Joins Heitman European Leadership Team13.7.2026 09:30:00 CEST | Press release
Heitman expands European platform with addition of experienced leader Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the appointment of Maureen Mahr von Staszewski as Managing Director in the firm’s European Real Estate Investment team. As part of Heitman’s European leadership team, Maureen will help drive continued expansion across Europe, supporting the firm’s strategic growth initiatives, capital raising efforts, and investment activity across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713202147/en/ Maureen Mahr von Staszewski Joins Heitman European Leadership Team “We are excited Maureen has joined the Heitman team,” said Caleb Mercer, Managing Director and Head of European Investment at Heitman. “Her breadth and depth of experience in European real estate investment management will help strengthen our innovative and differentiated investment capabilities acro
LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery13.7.2026 08:16:00 CEST | Press release
Claude and Claude Code embedded into LTM BlueVerse™ AI Delivery Fabric to power AI-led transformations LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows. LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains. The three strategic focus areas of partnership include:LTM BlueVerse™: AI Delivery Fabric LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into del
Sofinnova Partners Appoints David Evans as Partner13.7.2026 08:00:00 CEST | Press release
Sofinnova strengthens its growth strategy with a high-caliber London-based Partner:Physician-scientist combining frontline clinical experience, health financing and policy expertise, and a proven track record in venture capitalOver 20 years in drug development at Bristol Myers Squibb, Eli Lilly, and the Roche Venture Fund as well as in healthcare policy and financing Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom